文献速递泌尿生殖与妇科肿瘤放疗放疗物理与技术

前列腺癌淋巴结阳性根治性同步推量治疗中以前列腺为中心与以骨性标志为中心配准的剂量学比较

Prostate-Centric Versus Bony-Centric Registration in the Definitive Treatment of Node-Positive Prostate Cancer with Simultaneous Integrated Boost: A Dosimetric Comparison.
PubMed 文献 · Adv Radiat Oncol · 2022-03-16

本研究对15例临床淋巴结阳性前列腺癌患者的75次锥形束CT进行基准标记配准与骨盆骨性配准,分析41个淋巴结推量靶区的移位和剂量覆盖。基准标记配准下Dmin、Dmean、D95均显著低于骨性配准(P<.0001),淋巴结移位显著更高(P<.0001)。作者认为以前列腺内标记刚性配准摆位时,需较大且各向异性的PTV外扩才能充分覆盖淋巴结推量靶区。

要点

  • 基准标记配准下淋巴结推量靶区的Dmin、Dmean、D95均显著低于骨性配准(P<.0001)。
  • 基准标记配准下淋巴结移位显著高于骨性配准(P<.0001)。
  • 基准标记配准下多数方向3至5 mm大体淋巴结PTV外扩足够,但上方和后方需8至9 mm。

核心结论

  • 以前列腺内标记刚性配准进行摆位时,可能需要较大且各向异性的PTV外扩才能充分照射大体淋巴结靶区。
  • 作者认为可能需要自适应再计划等替代方法来克服这些局限性。

研究设计与样本

  • 对15例临床淋巴结阳性前列腺癌根治性放疗患者的75次锥形束CT进行基准标记配准和骨盆骨性配准至初始计划扫描。
  • 在每次锥形束CT配准上直接勾画淋巴结推量靶区的大体肿瘤体积,计算各配准下所有淋巴结靶区的移位和剂量覆盖。
  • 每个淋巴结的所有剂量归一化至其预定处方剂量(覆盖3 mm计划靶区体积外扩95%的剂量)。

主要发现

  • 共分析41个大体淋巴结靶区,其中80.5%(33/41)接受常规分割容积弧形调强放疗,19.5%(8/41)接受立体定向体部放疗。
  • 基准标记配准下Dmin、Dmean和D95均显著低于骨性配准(P<.0001)。
  • 基准标记配准下淋巴结移位显著更高(P<.0001)。
  • 基准标记与骨性配准之间的三维平移(骨性至基准标记向量)是淋巴结移位的最显著预测因素(P<.0001)。
  • 基准标记配准下,多数方向3至5 mm大体淋巴结PTV外扩足够,但由于前列腺不对称运动,上方和后方外扩需8至9 mm。

关键数值与推荐

  • 基准标记配准下Dmin、Dmean、D95均显著低于骨性配准(P<.0001)。
  • 基准标记配准下淋巴结移位显著高于骨性配准(P<.0001)。
  • 骨性至基准标记向量是淋巴结移位的最显著预测因素(P<.0001)。
  • 基准标记配准下多数方向3至5 mm大体淋巴结PTV外扩足够,上方和后方需8至9 mm。

临床怎么用

  • 作者认为以前列腺内标记刚性配准摆位时,可能需要较大且各向异性的PTV外扩以充分照射大体淋巴结靶区。
  • 作者认为可能需要自适应再计划等替代方法来克服这些局限性。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To determine the effect of daily shifts based on rigid registration to intraprostatic markers on coverage of boost doses delivered to gross nodal disease for prostate cancer. METHODS AND MATERIALS: Seventy-five cone beam computed tomographies (CBCTs) from 15 patients treated with definitive radiation for clinically node-positive prostate cancer underwent fiducial-based and pelvic bony-based registration to the initial planning scans. Gross tumor volumes of nodal boost targets were contoured directly on each CBCT registration. The nodal displacement (3-dimensional translation from the node centroid on planning CT to node centroid on registered CBCT) and dose coverage (minimum dose [Dmin], mean dose [Dmean], dose delivered to 95% of the gross tumor volumes [D95]) were calculated for each registration on all nodal targets. All doses for each node were normalized to its intended prescription dose (dose covering 95% of a 3 mm planning target volume [PTV] expansion). RESULTS: Forty-one gross nodal targets were analyzed. Most boosted nodes (80.5%, 33/41) were treated with conventional fractionation using volumetric-arc radiation therapy, and 19.5% (8/41) underwent stereotactic body radiation therapy (SBRT). Dmin, Dmean, and D95 were all significantly lower with fiducial-based registration compared with bony-based registration (P < .0001). Nodal displacement was significantly higher for fiducial-based registrations (P < .0001). The 3-dimensional translation between the fiducial-based and bony-based registrations (bony-to-fiducial vector) was the most significant predictor of nodal displacement (P < .0001). On fiducial-based registrations, a 3 to 5 mm gross nodal PTV margin is sufficient in most directions; however, superior and posterior margins of 8 to 9 mm are required as a result of asymmetrical prostatic motion. CONCLUSIONS: Large and anisotropic PTV margins are likely needed to adequately dose gross nodal targets when patient setup is based on rigid registration to intraprostatic markers. Alternative approaches such as adaptive replanning may be required to overcome these limitations.

来源:Adv Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Wu TC, Xiang M, Nickols NG, et al. Prostate-Centric Versus Bony-Centric Registration in the Definitive Treatment of Node-Positive Prostate Cancer with Simultaneous Integrated Boost: A Dosimetric Comparison. Adv Radiat Oncol. 2022. PMID: 35521072. doi:10.1016/j.adro.2022.100944

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。